KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

@article{Bilous2012KDOQICP,
  title={KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.},
  author={Rudy W. Bilous},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2012},
  volume={60 5},
  pages={
          850-86
        }
}
  • R. Bilous
  • Published 1 November 2012
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
The 2012 update of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Diabetes and Chronic Kidney Disease (CKD) is intended to assist the practitioner caring for patients with diabetes and CKD. Substantial high-quality new evidence has emerged since the original 2007 KDOQI guideline that could significantly change recommendations for clinical practice. As such, revisions of prior guidelines are offered that specifically address hemoglobin A(1c) (HbA(1c… 
View on PubMed
docum-enter.com
921 Citations
Highly Influential Citations
12
Background Citations
43
Methods Citations
11
Results Citations
2

921 Citations

Citation Type

Citation Type

KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.
TLDR
The 2015 update of the KDOQI Clinical Practice Guideline for Hemodialysis Adequacy is intended to assist practitioners caring for patients in preparation for and during hemodialysis.
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
TLDR
This synopsis focuses on 10 key recommendations pertinent to definition, classification, monitoring, and management of CKD in adults, and the full guideline included 110 recommendations.
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
  • L. Inker, B. Astor, +5 authors H. Feldman
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2014
TLDR
A work group agreed with most of the recommendations contained in the KDIGO guidelines, particularly the recommendations regarding the definition and classification of CKD, however, there were some concerns about incorporating the cause of disease into CKD classification.
Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
  • Y. Slinin, A. Ishani, +5 authors T. Wilt
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2012
TLDR
Evidence was insufficient to determine whether treatment of albuminuria in normotensive patients provides beneficial effects on clinical outcomes, and intensive glycemic control and lipid interventions did not improve clinical outcomes in patients with type 2 diabetes.
The Compatibility of the Treatment Modalities to the Recommendations of the Kidney Disease Outcomes Quality Initiative Guideline in Chronic Kidney Disease Patients with Diabetes
TLDR
Evaluated whether the treatment goals for CKD patients with DM are achieved under the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline, treatment goal for hyperglycemia was better achieved than the treatment Goals for hypertension and dyslipidemia.
Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals and recommendations.
TLDR
The ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care are highlighted.
Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines
TLDR
Guidelines generally agreed on management of patients with high risk or advanced CKD, but varied in regarding the range of recommended measurements, the need for referrals to nephrology, monitoring intervals and comprehensiveness.
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.
Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
TLDR
This KDIGO conference addressed a number of controversial areas in the management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate.
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
TLDR
Patients with NDD-CKD should be treated with statins and a BP target of 130/80 mmHg should be aimed for, and lifestyle modifications including smoking cessation, intentional weight loss, and regular physical activity should be recommended to those with CKD.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 129 REFERENCES
Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
  • Y. Slinin, A. Ishani, +5 authors T. Wilt
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2012
TLDR
Evidence was insufficient to determine whether treatment of albuminuria in normotensive patients provides beneficial effects on clinical outcomes, and intensive glycemic control and lipid interventions did not improve clinical outcomes in patients with type 2 diabetes.
Impact of the New K/DOQI Guidelines
TLDR
This article summarizes the recommendations of the first three set of clinical practice guidelines being developed under this new initiative: Chronic Kidney Disease: Evaluation, Classification and Stratification; Bone Metabolism and Disease in Chronic kidney disease, and Dyslipidemias in Kidney Failure.
Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
TLDR
Adaptations of the GRADE approach are presented to address some issues pertinent to the field of nephrology, including the need to extrapolate from studies performed predominantly in patients without kidney disease, and theneed to use qualitative summaries of effects when it is not feasible to quantitatively summarize them.
The burden of kidney disease: improving global outcomes.
TLDR
A new initiative "Kidney Disease: Improving Global Outcomes" has been established, its stated mission is to improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines.
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.
TLDR
It is suggested that appropriate and timely control of HbA(1c) level in people with DM and CKD may be more important than previously realized, but suggest also that intensive glycemic control (HbA (1C) level <6.5%) may be associated with increased mortality.
Effect of pravastatin in people with diabetes and chronic kidney disease.
TLDR
Stage 2 or early stage 3 CKD and diabetes both are associated with higher cardiovascular risk, and pravastatin reduces cardiovascular event rates in people with neither, one, or both characteristics.
Review: Metformin: Potential benefits and use in chronic kidney disease
TLDR
The use of metformin has been limited in patients with renal disease because of the perceived risk of lactic acidosis; however, it is likely that use of this drug would be beneficial in many with chronic kidney disease and suggestions for its clinical use are suggested.
Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
  • A. Levey, D. Cattran, +5 authors T. Hostetter
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2009
TLDR
There appears to be sufficient evidence to recommend changes in proteinuria as a surrogate for kidney disease progression in only selected circumstances, and collaboration among many groups, including academia, industry, the FDA, and the National Institutes of Health are recommended to share data from past and future studies.
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
TLDR
The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy.
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
TLDR
Patients with diabetes, stable coronary artery disease, and mild to moderate CKD experience marked reduction in cardiovascular events with intensive lipid lowering, in contrast to previous observations in patients with diabetes and end-stage renal disease.
...
1
2
3
4
5
...